Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
32.32
-0.37 (-1.13%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 927 employees as of February 15, 2024. The number of employees increased by 131 or 16.46% compared to the previous year.
Employees
927
Change (1Y)
131
Growth (1Y)
16.46%
Revenue / Employee
$760,667
Profits / Employee
-$489,641
Market Cap
5.14B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 15, 2024 | 927 | 131 | 16.46% |
Feb 16, 2023 | 796 | 136 | 20.61% |
Feb 16, 2022 | 660 | -97 | -12.81% |
Feb 18, 2021 | 757 | -60 | -7.34% |
Feb 20, 2020 | 817 | 80 | 10.85% |
Feb 20, 2019 | 737 | 190 | 34.73% |
Feb 20, 2018 | 547 | 112 | 25.75% |
Feb 21, 2017 | 435 | 7 | 1.64% |
Feb 19, 2016 | 428 | 38 | 9.74% |
Feb 17, 2015 | 390 | 86 | 28.29% |
Feb 17, 2014 | 304 | 16 | 5.56% |
Feb 11, 2013 | 288 | 7 | 2.49% |
Feb 13, 2012 | 281 | 11 | 4.07% |
Feb 14, 2011 | 270 | 20 | 8.00% |
Feb 10, 2010 | 250 | -50 | -16.67% |
Feb 10, 2009 | 300 | 0 | - |
Mar 1, 2008 | 300 | 26 | 9.49% |
Mar 5, 2007 | 274 | 16 | 6.20% |
Mar 3, 2006 | 258 | -45 | -14.85% |
Mar 3, 2005 | 303 | -154 | -33.70% |
Mar 3, 2004 | 457 | -66 | -12.62% |
Feb 28, 2003 | 523 | 89 | 20.51% |
Feb 28, 2002 | 434 | 131 | 43.23% |
Jan 31, 2001 | 303 | -49 | -13.92% |
Feb 25, 2000 | 352 | 6 | 1.73% |
Feb 26, 1999 | 346 | 8 | 2.37% |
Feb 27, 1998 | 338 | 51 | 17.77% |
Jan 31, 1997 | 287 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
IONS News
- 2 days ago - New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - Business Wire
- 3 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval - Seeking Alpha
- 3 days ago - Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - Benzinga
- 3 days ago - Ionis reports fourth quarter and full year 2024 financial results - Business Wire
- 17 days ago - Ionis to hold fourth quarter and full year 2024 financial results webcast - Business Wire
- 5 weeks ago - Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 - GlobeNewsWire
- 5 weeks ago - Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - PRNewsWire